BAX and lip and oral cavity carcinoma: Collectively, these results suggest that the anticancer activity of ZnO-PIP NPs in KB cells is mediated through the modulation of BCL2, BAX, and P53 expression levels, highlighting their potential as promising therapeutic agents for oral cancer treatment by targeting key apoptotic pathways.